Pharmacokinetics, Safety and Tolerability of Intravenous Lenzilumab, an Anti-GM-CSF Monoclonal Antibody Drug, in Healthy Korean Subjects.

Drug Des Devel Ther · 2025 · PMC12526383 · PMID 41104395

Europe PMC DOI

hedged sentence

0.2889

closest p · 5.8× alpha

0.2889

boldest claim

The sentences

did not reach statistical significancep -value = 0.2889not close (p > 0.1)

Although the 3 mg/kg cohort exhibited longer t 1/2 compared with the other two cohorts, the difference did not reach statistical significance (Kruskal–Wallis’s test, p -value = 0.2889).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.